Comparable stake leader
INTRACOASTAL CAPITAL, LLC
SEC ownership of PURPLE BIOTECH LTD.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001614744.
Disclosed value leader
INTRACOASTAL CAPITAL, LLC
Comparable rows
11/25
Latest evidence
31 Mar 2026
- Public ticker
- PPBT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
INTRACOASTAL CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
11 of 25
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
INTRACOASTAL CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001614744
- Issuer location
- Rehovot, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PURPLE BIOTECH LTD. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
INTRACOASTAL CAPITAL, LLC
Disclosed value leader
INTRACOASTAL CAPITAL, LLC
Comparable rows
11/25
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
14 rows are not safely comparable across share classes.
13D/G row: INTRACOASTAL CAPITAL, LLC
Showing 1-8 of 25 holder rows.
Quick read
INTRACOASTAL CAPITAL, LLC leads the comparable SEC ownership view at 10%.
11 of 25 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens INTRACOASTAL CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
INTRACOASTAL CAPITAL, LLC
10%
Lincoln Alternative Strategies LLC
9.9%
SUSQUEHANNA SECURITIES, LLC
5.2%
Orca Capital AG
4.9%
Gil Efron
0.56%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 25 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
10%
|
$124,305,955
282,513,535 shares
|
+$36,106,330 | 31 Mar 2026 |
| Lincoln Alternative Strategies LLC |
13D/G
|
9.9%
|
$1,288,650
605,000 shares
|
$0 | 04 Sep 2025 |
| SUSQUEHANNA SECURITIES, LLC |
13D/G
|
5.2%
|
$63,888,312
93,953,400 shares
|
$0 | 31 Dec 2025 |
| Orca Capital AG |
13D/G
|
4.9%
|
$652,619
306,394 shares
|
$0 | 04 Sep 2025 |
| Gil Efron |
3/4/5
Chief Executive Officer
|
0.56%
|
$10,355,625
15,750,000 shares
|
— | 18 Mar 2026 |
| Michael Schickler |
3/4/5
Head of Clinical & Reg Affairs
|
0.33%
|
$6,084,815
9,254,472 shares
|
— | 18 Mar 2026 |
| Shai S. Lankry |
3/4/5
Chief Financial Officer
|
0.13%
|
$2,334,125
3,550,000 shares
|
— | 18 Mar 2026 |
| Simcha Rock |
3/4/5
Director
|
0.11%
|
$1,411,384
3,207,690 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to PURPLE BIOTECH LTD.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
Gil Efron
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Gil Efron | Chief Executive Officer | $10,355,625 | Mixed | 18 Mar 2026 | ||
| Michael Schickler | Head of Clinical & Reg Affairs | $6,084,815 | Mixed | 18 Mar 2026 | ||
| Shai S. Lankry | Chief Financial Officer | $2,334,125 | Mixed | 18 Mar 2026 | ||
| Ido Agmon | Director | $2,034,212 | Mixed | 18 Mar 2026 | ||
| Robert E. Gagnon | Director | $1,531,250 | Mixed | 18 Mar 2026 | ||
| Simcha Rock | Director | $1,411,384 | Market | 18 Mar 2026 | ||
| Suzana Zilberberg | Director | $1,347,500 | Market | 18 Mar 2026 |
Recent insider transactions for PURPLE BIOTECH LTD.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Simcha Rock | PPBT | Ordinary Shares | 0 | 3,207,690 | 18 Mar 2026 | Direct | ||||
| Suzana Zilberberg | PPBT | Ordinary Shares | 0 | 3,062,500 | 18 Mar 2026 | Direct | ||||
| Ido Agmon | PPBT | Ordinary Shares | 0 | 3,093,860 | 18 Mar 2026 | Direct | ||||
| Gil Efron | PPBT | Ordinary Shares | 0 | 15,750,000 | 18 Mar 2026 | Direct | ||||
| Shai S. Lankry | PPBT | Ordinary Shares | 0 | 3,550,000 | 18 Mar 2026 | Direct | ||||
| Michael Schickler | PPBT | Ordinary Shares | 0 | 9,254,472 | 18 Mar 2026 | Direct | ||||
| Robert E. Gagnon | PPBT | Ordinary Shares | 0 | 3,062,500 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.